期刊
CURRENT ONCOLOGY REPORTS
卷 19, 期 2, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-017-0567-8
关键词
Carcinoid tumors; PRRT; Radiolabeled somatostatin analogs; Lutetium; NETTER-1
类别
资金
- Novartis
- Advanced Accelerator Applications
Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, Y-90-DOTATOC and Lu-177-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared Lu-177-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据